Stay updated on Ibrutinib Combo in Metastatic Pancreatic Adeno Clinical Trial
Sign up to get notified when there's something new on the Ibrutinib Combo in Metastatic Pancreatic Adeno Clinical Trial page.

Latest updates to the Ibrutinib Combo in Metastatic Pancreatic Adeno Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has been updated to include the study identifier PCYC-1137-CA and the latest revision number v2.15.0, while significant details about the study's design and inclusion/exclusion criteria have been removed.SummaryDifference11%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to Ibrutinib Combo in Metastatic Pancreatic Adeno Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ibrutinib Combo in Metastatic Pancreatic Adeno Clinical Trial page.